Company intelligence / Profile preview

LineaRx

Stony Brook, New York, United Stateslinearxdna.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Early data demonstrated successful expression of PCR-generated genes such as GFP in human T cells ex vivo. The anti-CD19 construct showed complete remissions in small patient cohorts when delivered via viral vectors previously; current efforts focus on replicating efficacy with nonviral linear-DNA approaches[7]. Vaccine candidates have shown tumor reduction signals preclinically[8].

Therapeutic areas: OncologyHematology
Modalities: Linear DNA constructs for gene therapy and cellular therapiesmRNA production templates via enzymatic methodsNonviral plasmid-free CAR T cell therapiesAnti-cancer vaccines based on linear-DNA platforms
Industry: Biotech

Drug pipeline

2 assets

LinCART19

Preclinical

1 more asset in the full pipeline.

Request access →

Partnerships

iCell Gene TherapeuticsTakis/Evvivax

Beyond the preview

Go deeper on LineaRx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LineaRx.

Explore the full profile